Collaborative Arrangement, Maximum Contingent Payments, Amount

No definition available.

Name:	ipxl_CollaborativeArrangementMaximumContingentPaymentsAmount
Namespace Prefix:	ipxl_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Collaborative Arrangement Profit Share Percentage

+ References

No definition available.

+ Details

Name:	ipxl_CollaborativeArrangementProfitSharePercentage
Namespace Prefix:	ipxl_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Collaborative Arrangement Reduced Royalty, Amount

+ References

No definition available.

+ Details

Name:	ipxl_CollaborativeArrangementReducedRoyaltyAmount
Namespace Prefix:	ipxl_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Collaborative Arrangement, Term

+ References

No definition available.

+ Details

Name:	ipxl_CollaborativeArrangementTerm
Namespace Prefix:	ipxl_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Collaborative Arrangement Up Front Payment

+ References

No definition available.

+ Details

Name:	ipxl_CollaborativeArrangementUpFrontPayment
Namespace Prefix:	ipxl_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Number of Products

+ References

No definition available.

+ Details

Name:	ipxl_NumberOfProducts
Namespace Prefix:	ipxl_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2(a),(d))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

+ Details

Name:	us-gaap_CostOfGoodsAndServicesSold
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=ipxl_BiosimilarLicensingAndSupplyAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=ipxl_AdelloBiologicsLLCLicenseAndCommercializationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=ipxl_AstraZenecaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_RoyaltyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ipxl_MilestonePaymentAxis=ipxl_RegulatoryApprovalMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ipxl_MilestonePaymentAxis=ipxl_SuccessfulDeliveryOfCommercialLaunchInventoryMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ipxl_MilestonePaymentAxis=ipxl_NumberOfCompetitorsForLaunchOfOneProductMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ipxl_MilestonePaymentAxis=ipxl_AchievementOfCumulativeNetSalesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Alliance and Collaboration (Details) $ in Thousands				3 Months Ended		6 Months Ended
Alliance and Collaboration (Details) $ in Thousands	May 07, 2018 USD ($)	Oct. 01, 2017 USD ($) product	Jun. 30, 2016 USD ($)	Jun. 30, 2018 USD ($)	Jun. 30, 2017 USD ($)	Jun. 30, 2018 USD ($)	Jun. 30, 2017 USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and development				$ 50,335	$ 47,184	$ 94,544	$ 86,603
Cost of sales				235,492	$ 136,138	366,086	$ 245,803
Biosimilar Licensing and Supply Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative arrangement maximum contingent payments amount	$ 71,800
Research and development				500		500
Adello Biologics, LLC License and Commercialization Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Number of products \| product		2
Collaborative arrangement term		10 years
Collaborative arrangement up front payment		$ 1,500
Collaborative arrangement profit share percentage		50.00%
Astra Zeneca
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative arrangement reduced royalty			$ 30,000
Royalty \| Astra Zeneca
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Cost of sales				$ 1,000		$ 1,000
Regulatory Approval \| Adello Biologics, LLC License and Commercialization Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative arrangement maximum contingent payments amount		$ 21,000
Successful Delivery of Commercial Launch Inventory \| Adello Biologics, LLC License and Commercialization Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative arrangement maximum contingent payments amount		43,000
Minimum \| Number of Competitors for Launch of One Product \| Adello Biologics, LLC License and Commercialization Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative arrangement maximum contingent payments amount		20,000
Minimum \| Achievement of Cumulative Net Sales \| Adello Biologics, LLC License and Commercialization Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative arrangement maximum contingent payments amount		15,000
Maximum \| Number of Competitors for Launch of One Product \| Adello Biologics, LLC License and Commercialization Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative arrangement maximum contingent payments amount		50,000
Maximum \| Achievement of Cumulative Net Sales \| Adello Biologics, LLC License and Commercialization Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative arrangement maximum contingent payments amount		$ 67,500